Gerry McCauley MPharm is the company founder and inventor of OmniSpirant’s patent pending inhaled EV (exosome) technology. Gerry is a qualified pharmacist and entrepreneur with extensive commercial, regulatory & startup experience and previous inhaled drug/device development expertise. OmniSpirant assembled and successfully led the INSPIRE consortium - awarded €13.4M from Horizon Europe to develop OS003, an OmniSome based lung cancer treatment. OmniSpirant is a recipient of the European Union Seal of Excellence for H2020 SME Instrument, October 2020 (OmniSomes, 969832, Developing a novel regenerative gene therapy platform technology for inhaled treatment of CF and other lung diseases) as an endorsement of the company, team and the project's quality. In March 2021 StartUS insights named OmniSpirant in the world's top 5 startups developing drugs for respiratory disease (from global analysis of 271 companies). OmniSpirant were European Health Catapult finalists in the biotech category, 2019.